Genmab and AbbVie Announce Positive Topline Results from
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities...
Source: globenewswire.com
Page 6 - Treatment Patterns News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Treatment Patterns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Treatment Patterns Today - Breaking & Trending Today
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™...
Source: prnewswire.com
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
Results from phase 1/2 EPCORE NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98 percent overall response rate (ORR), 87 percent complete metabolic
Source: finanznachrichten.de
Verana Health's Qdata Geographic Atrophy Links EHR And Imaging Data To Provide A Holistic View Of The Patient Journey
Verana Health® - a digital health company elevating quality in real-world data (RWD)— will announce the development of Qdata®...
Source: healthitoutcomes.com
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® tablets The U.S. Food and Drug Administration ... | April 11, 2023
Source: marketscreener.com